No Data
Express News | Immatics NV : Mizuho Raises Target Price to $16 From $14
Nearly 90% of patients have shrinking tumors! Immatics (IMTX.US) innovative cell therapy phase 2/3 trial is about to begin
iMA203 is a TCR-T cell developed by IMMatics' proprietary ActenGine platform and targets the melanoma antigen PRAME presented by HLA-A*02.
Immatics' Q1 Loss Narrows. Revenue Rises
Immatics (IMTX) reported a Q1 net loss Tuesday of 0.04 euros ($0.043) per diluted share, narrowing from a loss of 0.26 euros a year earlier. Three analysts polled by Capital IQ expected a loss of 0.27
6-K: Report of foreign private issuer (related to financial reporting)
Immatics: Runway Funding Company Operations Into 2027 >IMTX
Immatics: Runway Funding Company Operations Into 2027 >IMTX
Immatics 1Q Loss EUR3.05M >IMTX
Immatics 1Q Loss EUR3.05M >IMTX